VRDN

Viridian Therapeutics, Inc.

NasdaqCMUSDEQUITY DELAYED

24.50

■ 0.00 (0.00%)

MARKET · —

Price

Open

24.00

Prev close

24.50

Day high

24.74

Day low

24.07

Volume

893.83K

Market cap

—

P/E (TTM)

—

52W range

13.18 – 34.29

Trailing performance

Price return · vs SPY

Returnvs SPY

+10.01% +11.4%

+26.12% +22.4%

+37.31% +34.2%

-11.48% -22.5%

YTD

-21.95% -34.2%

+33.90% +13.9%

+24.95% -49.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

23.36

+4.88% from price

SMA 20

21.94

+10.71% from price

SMA 50

19.75

+23.00% from price

SMA 100

17.83

+37.40% from price

SMA 200

23.98

+1.31% from price

EMA 12

23.13

+5.91% from price

EMA 26

21.77

+12.54% from price

EMA 50

20.55

+19.25% from price

RSI (14)

68.6

Neutral

MACD (12,26,9)

1.36

Hist 0.18

ATR (14)

1.06

4.36% of price

Realised vol 30D

48.9%

Annualised

Bollinger upper

25.66

20, 2σ

Bollinger lower

18.22

20, 2σ

50 / 200 cross

Death

19.75 vs 23.98

Trend bias

Above 200

+1.31%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.10

More volatile than market

Correlation to SPY

0.20

Largely independent

Realised vol 30D

48.9%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-60.6%

Peak to trough

Max drawdown 5Y

-70.7%

Peak to trough

ATR 14

1.06

4.36% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 24.50

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

VRDN · links out to the publisher

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says MT Newswires · 15d ago RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating MT Newswires · 15d ago Wedbush Adjusts PT on Viridian Therapeutics to $41 From $43, Maintains Outperform Rating MT Newswires · 16d ago Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results Business Wire · 16d ago Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight PR Newswire · 24d ago Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) Insider Monkey · 38d ago Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? Simply Wall St. · 38d ago Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today Simply Wall St. · 38d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.